

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED  
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Hyderabad-500008.  
CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2022

Rupees in Lakhs

Sl.No	Particulars	Quarter Ended			Year Ended	
		31-03-2022	31-12-2021	31-03-2021	31-03-2022	31-03-2021
		Audited	Un Audited	Audited	Audited	Audited
1	<b>Income</b>					
	(a) Revenue From Operations	1192.35	2101.77	1537.28	6779.30	4787.59
	(b) Other Income	511.62	38.87	9.13	592.44	93.91
	(c) Unbilled Revenue	0.00	0.00	0.00	0.00	53.00
	<b>Total income</b>	<b>1,703.97</b>	<b>2,140.64</b>	<b>1,546.41</b>	<b>7,371.74</b>	<b>4,934.50</b>
2	<b>Expenses</b>					
	(a) Cost of Material Consumed	51.59	90.73	117.14	369.43	274.55
	(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	125.30	129.58	-33.70	369.93	-210.30
	(c) Employee benefit expense	643.95	507.12	360.33	2052.19	1253.34
	(d) Finance Cost	19.50	22.17	15.24	96.30	209.36
	(e) Depreciation and Amortisation expense	71.45	98.38	98.63	368.88	396.83
	(f) Other Expenses	583.24	700.83	605.76	2312.19	1645.78
	<b>Total Expenses</b>	<b>1,495.03</b>	<b>1,548.81</b>	<b>1,163.40</b>	<b>5,568.92</b>	<b>3,569.56</b>
3	Profit before exceptional items and Tax	208.94	591.83	383.01	1,802.82	1,364.94
4	Add(+)/ Less(-) Exceptional items	-	-	-	-	-
5	Profit/ (Loss) before Tax	208.94	591.83	383.01	1,802.82	1,364.94
6	Tax Expenses	147.40	164.77	-1.22	608.46	190.94
7	Profit(Loss) for the Period from Continuing Operations	61.54	427.06	384.23	1,194.36	1,174.00
8	Profit(Loss) from Discontinuing Operations	-	-	-	-	-
9	Tax Expenses on discontinuing Operations	-	-	-	-	-





Sl.No	Particulars	Quarter Ended			Year Ended	
		31-03-2022	31-12-2021	31-03-2021	31-03-2022	31-03-2021
		Audited	Un Audited	Audited	Audited	Audited
10	Profit(Loss) from Discontinuing Operations after Tax		-	-		-
11	Profit(Loss) for the period	61.54	427.06	384.23	1,194.36	1,174.00
12	Other Comprehensive Income:					
	A (i) Items that will not be reclassified to profit or loss	18.66	1.11	6.80	21.03	5.96
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
13	Total Comprehensive Income for the period	80.20	428.17	391.03	1,215.39	1,179.96
14	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,530.15	1,530.15	1,530.15	1530.15	1530.15
15	Other equity excluding revaluation reserve					1972.12
16	Earnings per Equity share ( for continuing operations)					
	a) Basic (Amount in Rupees)	0.52	2.80	2.56	7.94	7.71
	b) Diluted (Amount in Rupees)	0.52	2.80	2.56	7.94	7.71
17	Earnings per Equity share ( for discontinued operations)					
	a) Basic (Amount in Rupees)					
	b) Diluted (Amount in Rupees)					
18	Earnings per Equity share ( for Continuing & discontinued operations)					
	a) Basic (Amount in Rupees)	0.52	2.80	2.56	7.94	7.71
	b) Diluted (Amount in Rupees)	0.52	2.80	2.56	7.94	7.71

#### Notes to the Consolidated Audited Financial Results

- The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015
- The above results have been reviewed by the Audit Committee at its meeting held on 30.05.2022 and approved by the Board of Directors of the Company on the same date.
- The Group currently has two segments (i) clinical research services and (ii) Information technology services.
- The company has considered the possible effects that may result from the pandemic relating to Covid 19 on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. In developing the assumptions relating to the future possible uncertainties in the global economic conditions, the Company has, at the date of approval of these standalone financial results, used internal and external sources of information, including economic forecasts and estimates from market sources, on the expected future performance of the company. On the basis of evaluation and current indicators of future economic conditions, the Company expects to recover the carrying amounts of the above assets and does not anticipate any impairment to these financial and non -financial assets. However, the impact assessment of Covid-19 is a continuing process, given the uncertainties
- The figures for the 4th quarter are the balancing figures between audited figures in respect of the full Financial Year and published un audited Year to date figures up to the 3rd quarter of the relevant financial year.
- The above consolidated financial results include the Un Audited financial results of the wholly owned subsidiaries, M/s Enhops Solutions Pvt Ltd & Enhops Inc upto 31.01.2022.
- Other Income includes Rs.404.22 Lakhs on Profit on Sale of Investments in subsidiary companies
- Employee benefit expenses includes Rs. 262.60 Lakhs towards ESOP provided as per " Ind AS 102 - Share Based Payments"
- The Board of Directos have Recommended a Final Dividend @12% i.e Rs.1.20 per share (Face Value of Rs. 10 each) for the year ended 31st March, 2022 on Paidup Capital of the Company.
- Figures for the previous periods have been rearranged wherever necessary.




SEGMENT-WISE REVENUE, RESULTS & CAPITAL EMPLOYED ( Consolidated Unaudited )  
UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR THE YEAR ENDED 31ST MARCH, 2022

Particulars	Quarter Ended			Year Ended	
	31-03-2022	31-12-2021	31-03-2021	31-03-2022	31-03-2021
	Audited	Un Audited	Audited	Audited	Audited
<b>SEGMENT REVENUE: (Net Sales / Income from Operations)</b>					
a) Clinical Research Services	1,172.48	1,645.28	1,363.74	5,842.25	4,284.79
b) Information Technology Services	127.27	495.36	182.67	1125.27	649.71
c) Profit on Sale of Investments	404.22	-	-	404.22	-
Total:	1,703.97	2,140.64	1,546.41	7,371.74	4,934.50
LESS: Inter Segment revenue		-			-
Net Sales/income from Operations.	1,703.97	2,140.64	1,546.41	7,371.74	4,934.50
<b>SEGMENT RESULTS : PROFIT / (LOSS) BEFORE TAX AND INTEREST</b>					
a) Clinical Research Services	-21.99	567.72	361.47	1,526.98	1,489.47
b) Information Technology Services	-153.79	46.27	36.78	(32.08)	84.83
c) Profit on Sale of Investments	404.22			404.22	
Total:	228.44	613.99	398.25	1,899.12	1,574.30
LESS:					
i) Interest	19.50	22.17	15.24	96.30	209.36
ii) Other Un-Allocable Expenditure	-	-	-	-	-
iii) Un-Allocable Income	-	-	-	-	-
<b>TOTAL PROFIT /(-LOSS) BEFORE TAX</b>	208.94	591.82	383.01	1,802.82	1,364.94

Place:Hyderabad  
Date:30.05.2022

for Jeevan Scientific Technology Limited  
On behalf of the Board of Directors

  
K. Krishna Kishore  
Vice Chairman & Managing Director

  
M Srikanth Sasidhar  
CFO

